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SUMMARY
Von Hippel Lindau disease (vHL), an autosomal dominant precancerous
condition, had segregated in a large kindred. Fourteen relatives were
known to have been affected; record reviews disclosed features of vHL
in 15 previously undiagnosed relatives; presymptomatic evaluations de-
tected vHL in 13 additional members of this kindred. Altogether, among
220 descendants of an ancestral couple, 41 had vHL.
We screened for HLA haplotypes and for polymorphic gene markers
at 31 loci in 102 direct descendants and 16 spouses from this kindred,
including 23 with vHL. Linkage analyses failed to reveal a significant
lod score with any locus tested, or any HLA linkage disequilibrium.
Expression of vHL among the affected relatives was compared with
384 other reported cases of vHL. The age of onset, tissue involvement,
and life expectancy in this family were similar to the other reported
cases. The sigmoid age-of-onset distribution for vHL most closely
matched a square-foot transformation (mean = 26.2-2 years; variance
= 1.224).
INTRODUCTION
Von Hippel-Lindau disease (vHL) is an autosomal dominant, pleiotropic, pre-
cancerous condition, producing cysts and solid tumors in the retina, central nervous
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system, kidneys, pancreas, and elsewhere. It causes retinal, posterior cranial
fossa, spinal cord, renal, and pancreatic malignancies [1, 2]. Since 1926, over
384 cases of vHL have been reported in the English-language literature [1-5].
The disease has been found among Africans, Europeans, and Orientals. An in-
dividual with the vHL genotype appears to be susceptible to any of its lesions in
any combination and in any sequence. The onset of first symptoms is usually
between ages 20 and 50, but it has presented in newborn infants and in individuals
as old as age 80.
We studied a large kindred that had 14 members known to be affected with
vHL, all related via a founder couple, ascertained by us through one proband
(fig. 1) [2, 5-11].
Investigations in this family were conducted with the following goals: (1) to
determine whether this family had typical vHL; (2) to assess the heterogeneity
of vHL within this family; (3) to compare this kindred with published cases for
age of onset, tissue involvement, and natural history; and (4) to seek linkage of
vHL to a gene marker, for estimating the risk for vHL among presymptomatic
relatives.
Clinical aspects to detect affected patients, to screen for presymptomatic subjects
with vHL, and to provide timely treatment are presented elsewhere [2, 5, 7-11].
SUBJECTS AND METHODS
The Kindred
The family consisted of 220 individuals in 5 generations (fig. 1), all directly descended
from an immigrant Puerto Rican couple, subjects I-1 and I-2, and their two children, II-
1 and II-2. A partial pedigree, based on record linkage data, has been reported independently,
with some errors [12]. Table 1 lists data for the 42 affected individuals, including the 13
new cases that were detected by screening.
Methods
Pedigree information was obtained from members of the kindred. Patient records, surgical
findings, and autopsy histology were examined when available. All surviving direct de-
scendants of subjects I- 1 and 1-2 who were over age 6 and the spouses of direct descendants
were invited to participate in a project that included clinical evaluations, presymptomatic
testing for evidence of vHL [2, 5, 7-10], and gene-linkage studies.
Lymphocytes were obtained for HLA serotyping [13]; whole blood, urine, and parotid
saliva were shipped promptly on ice to the University of North Carolina for gene-marker
studies.
The following autosomal markers were analyzed: ABO, Rhesus (RhC, RhD, RhE),
MN, Kell, P, Kidd (Jk), Lutheran (Lu), Duffy (Fy), Km, Gm, pancreatic amylase (AMY2),
phosphogluconate dehydrogenase (PGD), adenosine deaminase (ADA), adenylate kinase
(AKI), phosphoglucomutase I (PGM1), haptoglobin (HP), group specific protein (GC),
orosomucoid (ORM), esterase D (ESD), glyoxalase I (GLO), acid phosphatase I (ACP1),
third component of complement (C3), uridine monophosphate kinase (UMPK), properdin
factor B (BF), erythrocyte glutamic-pyruvic transaminase (GPT1), Lewis (Le), secretor
(Se), hexose-6-phosphate dehydrogenase (H6PD), and double band (DB). These represent
28 loci, known to be localized on at least 11 arms of 10 autosomes (table 2). Techniques
used to identify these markers are described elsewhere [14-16].
Segregation analysis using Bernoulli's incompletely dominant genetic model derived
the best estimates of genotype for offspring in each sibship. This allowed for uncertainties
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in gene assignments [17-20], because many younger family members must have been
heterozygous but had not yet become affected. Lod scores were calculated ([21] and
R. C. Elston and E. B. Kaplan, GENPED-A general pedigree analysis program, personal
communication, 1973) for recombination values from 0 to .45 at .05 increments; lod
scores > +3.0 were to be considered significant.
Age of onset can be defined as the age at medical intervention, the age of first symptoms,
or the age at presymptomatic detection. In our calculations of symptomatic age of onset,
the patients we detected presymptomatically were omitted. These data were compared
with and then combined with data from the 384 vHL cases described in the English-
language literature [2, 7]. Age of symptomatic onset or diagnosis was calculated for a
total of 340 published cases with adequate data and for 23 cases from this kindred [2,
10].
RESULTS
Out of this kindred, 102 direct descendants and 16 surviving spouses of de-
scendants, in 43 sibships, participated in the gene-linkage study, including 26
individuals who showed manifestations of vHL (fig. 1). Its most frequent man-
ifestations were retinal hemangioblastoma (affecting 22), renal cysts and carcinoma
(affecting 23), and cerebellar or spinal hemangioblastoma (affecting 18).
The diagnosis of vHL had been made prior to our study in 14 patients, six
presymptomatically; we made the diagnosis of vHL retrospectively in 15 affected,
and detected 13 new cases, including two, subjects IV-49 and IV-66, who developed
symptoms after initial screening had been negative. The segregation of affected
individuals in this kindred was entirely consistent with a single major autosomal
allele, dominant in expression. Both sexes were equally affected, with male-to-
male transmission. Seventeen affected parents in generations I-III had 38 affected
and 51 unaffected children (discounting eight who had died in infancy). In gen-
eration IV, 13 affected parents had 38 children; only three of these have become
affected so far. Expression was .77 for presumed heterozygotes, and < .003 for
probable nonheterozygotes.
The clinical manifestations of vHL in the patients from this kindred were
compared with 384 other published cases. Close similarities were found in age
of onset, tissues affected, malignant propensity, and life expectancy, except that
thorough perusal of medical records and screening failed to detect polycythemia
or pheochromocytoma in any patient from this kindred. Patterns of expression
were similar in the different branches of this kindred.
None of the lod scores for 27 informative loci was linked to susceptibility for
vHL; salivary protein DB was not informative. Negative lod scores, Z S -2.0,
strongly suggested nonlinkage to: Rh, MN, P, Jk, Lu, Fy, PGM1, HP, GC, ORM,
ESD, UMPK, BF, GPT1, Le, Se, and H6PD. No linkage disequilibrium was
found with any HLA type; this was supported by the negative lod scores for BF,
in the major histocompatibility region of chromosome 6p. The highest lod score
was +.74 for GPT, at recombination fraction . 10 (table 2).
Chromosome-banding studies (by Dr. P. A. Jacobs, University of Hawaii)
failed to identify any structural abnormalities or any informative familial seg-
regation of polymorphic markers in key affected and unaffected relatives.
The age-of-onset distributions showed no significant differences between the
23 subjects who presented with symptoms in this family and 340 other published
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LOD SCORES BETWEEN THE vHL SUSCEPTIBILITY GENE AND 27 MARKER Loci, WITH PROBABLE
CHROMOSOME LOCATIONS [31, 32]
CHROMOSOME RECOMBINATION FRACTIONS
Marker Location 0 .10 .20 .30 .40
ABO ....... 9q34 -0.94 -0.59 -0.37 -0.21 -0.08
RhC ....... lp36-p32 -8.01 -1.88 -0.84 -0.36 -0.12
RhD ....... lp36-p32 +0.06 +0.03 0.00 -0.01 -0.01
RhE ....... lp36-p32 -6.36 -1.58 -0.78 -0.34 -0.01
MN ........ 4q28-q31 -15.58 -3.62 -1.53 -0.61 -0.19
Kell ....... ... -1.15 -0.58 -0.33 -0.17 -0.07
P ........ 6 -5.99 -2.01 -1.33 -0.81 -0.38
Jk ........ 2 -2.92 -1.41 -0.67 -0.28 -0.08
Lu ........ * -10.02 -3.26 -1.60 -0.69 -0.22
Fy ........ lql3 -13.94 -3.17 -1.36 -0.57 -0.22
Km ........ ... -3.64 -0.46 +0.37 +0.58 +0.43
Gm ........ * -1.28 -0.58 -0.27 -0.11 -0.04
AMY2 ...1..lp22.1-ql 1 -0.08 -0.04 -0.02 -0.01 -0.00
PGD ....... iIpter-p34 -0.40 -0.24 -0.15 -0.07 -0.03
ADA ....... 20qI3.2-ter +0.05 +0.04 +0.03 +0.02 +0.01
AKI ....... 9q34 -0.01 -0.01 0.00 0.00 0.00
PGM1 ...... lp22.1 -7.26 -1.63 -0.82 -0.38 -0.13
HP ........ 16cen-q22 -13.23 -3.36 -1.32 -0.38 -0.02
GC ........ 4qll-ql3 -2.87 -1.26 -0.59 -0.27 -0.09
ORM ...... 9q34 -9.08 -2.46 -1.06 -0.36 -0.05
ESD ....... 13q14 -13.36 -3.87 -1.91 -0.92 -0.34
GLOI ...... 6p22-p2l +0.06 +0.47 +0.61 +0.56 +0.35
ACP1 ...... 2p23 or p25 -0.89 -3.77 -1.95 -0.92 -0.31
C3 ........ 19 +0.19 +0.17 +0.13 +0.09 +0.04
UMPK ..... lp32 -7.05 -1.68 -0.30 +0.20 +0.27
BF ........ 6p23-p2105 -9.34 -2.33 -1.23 -0.54 -0.20
GPTI ...... 16pter-pl 1 -2.71 +0.74 +0.67 +0.49 +0.27
Le ........ ... -2.41 +0.69 +0.65 +0.43 +0.07
Se ........ 19 -2.91 -1.19 -0.58 -0.28 -0.11
H6PD ..... ... -2.91 -1.19 -0.58 -0.28 -0.11
NOTE: Lod scores at recombination fraction (OM = OF)-
cases; the combined age-of-onset distribution of these 363 cases better matched
a square-root transformation (mean: 26.2-2 years; variance: 1.224) than a log-
arithmic transformation (fig. 2).
DISCUSSION
Virtually all published cases of vHL have had affected relatives [ 1-4], consistent
with autosomal dominant transmission. The two sexes were equally -affected,
with affected father-son pairs. Occasional skipped generations have been attributed
to variable age of onset. The single claim of a family with autosomal recessive
inheritance has been retracted because vHL was subsequently expressed in key
relatives ([22] and M. H. K. Shokeir, discussion at presentation of [6], Vancouver,
October 1978).
Our kindred is the largest known in which the vHL gene has segregated, affecting
the most relatives. Subject I-1 had several reportedly unaffected children from
previous marriages, and subject 1-2 had remarried twice and had borne five other
unaffected children (11-3-11-7), yet the only two children born to this couple
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were both affected, and in the next generation, among the 20 surviving beyond
childhood, 15 were affected. The vHL gene in this kindred followed an autosomal
dominant segregation pattern, modified by variable age of symptomatic onset;
subject 111-2 was asymptomatic until age 64. No obligate heterozygote has failed
to express the phenotype; the only apparent exception, subject IV-49, later presented
with seizures due to cerebellar hemangioblastomata (fig. 1, table 1). Generations
V and VI of our kindred must still contain many heterozygous presymptomatic
children and grandchildren of the affected who were undetected by screening
because of their youth.
It was disappointing that the diagnosis of vHL had been missed by the physicians
caring for many of the affected relatives, and disturbing that even when the
diagnosis had been made, relatives were not told, screened, or given genetic
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FIG. 2.-Cumulative observed age-of-onset distribution for 363 vHL patients, plotted according
to a square-root transformation (crosses), compared with the expected cumulative square-root normal
(steeper line), and expected cumulative normal distributions.
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for retinal lesions by ophthalmologists, but only the physicians and geneticists
looking after subject 111-24 checked thoroughly for vHL lesions in immediate
relatives and gave genetic counseling, including advice that his relatives should
be screened for manifestations of vHL [23].
Patients from this kindred did not differ substantially from 384 reported vHL
cases [2, 101, except for the absence of pheochromocytoma and polycythemia.
Polycythemia had been recorded in 10%-20% of vHL patients who had cerebellar,
renal, or suprarenal tumors [ 1, 2]. Pheochromocytoma was reported in 69 of 384
patients with vHL (15 of 88 autopsied cases [2, 24]). These differences could be
due to variable pleiotropic expression of a single mutant allele of major dominant
effect, or to statistical variability in the small numbers available for comparison.
The sigmoid age-of-onset distribution for vHL (fig. 2) was analogous to that
for Huntington disease [25]. This distribution can be useful for calculating het-
erozygote probabilities for asymptomatic relatives of vHL patients [26]. Although
the distribution gave remarkably close fit to a square-root transformation, this
fit has no recognized biological significance.
Severity did not correlate with the distribution of lesions, since some vHL
patients never developed retinal or neural tumors (e.g., subjects I11-2 and IV-3,
table 1), and others never had renal involvement, even when they survived to
late adulthood (subject 111-10 [2, 6]). Small retinal and neural lesions would be
much more likely to produce symptoms than renal or pancreatic lesions of a
comparable size, while epididymal tumors would rarely cause an individual to
seek medical attention, most often being an incidental finding, as in our seven
cases.
Analyses for gene-linkage in a single kindred with many informative matings
has important advantages over studies on multiple smaller unrelated families. It
provides opportunity to study the expression of a common ancestral gene among
many descendants, and gene linkages are less likely to be obscured by chance
crossings-over, because these would distort linkage associations in only one
branch of the family. This was the justification for our gene marker project [27,
28], and the basis for our strategy. Our failure to identify linkage of vHL with a
known gene marker was disappointing but not surprising, since major regions of
the human genome remain unmapped and not closely linked to known markers.
We estimate that the prior probability of finding detectable linkage with the loci
we studied is .37 [29-32]. Negative linkage data from this large kindred are still
of value, since these lod scores can be incorporated into future studies.
Since an ever-increasing number of restriction endonuclease polymorphic sites
are being mapped, studies using DNA polymorphisms would be the next logical
step for identifying and localizing the vHL gene [33, 34].
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